Market Report Source

Overview

Introduction

QLT was originally focused on discovering, developing and commercializing innovative therapies in the fields of ophthalmology and dermatology. In 2006, the company changed its focus to purely research and development by selling its manufacturing facility to Tolmar Pharmaceuticals.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

QLT has two marketed products: Visudyne for the treatment of wet age-related macular degeneration (AMD), pathologic myopia and presumed ocular histoplasmosis and Eligard for the palliative treatment of advanced prostate cancer. QLT derives its revenues form of product sales (net product revenue and royalties), contract research and development, and licensing and milestones. The company enters into commercial license agreements with pharmaceutical and biotechnology companies to market its products. The company’s total revenues increased at a CAGR of 11.9% during 2002-2006, from $110.5 million to $175.1 million. This represents an absolute total growth of +$64.6 million for total revenues. The company’s biggest contributor to revenue growth during 2002-2006 was product sales of Visudyne and Eligard.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Geographic Segment Performance
Products & Services
Marketed Products
Pipeline Products
Historical Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview

APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: QLT – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Figure 2: QLT – Key Strategic Revenues, 2002-2006 ($ Mn)

TABLES
Table 1: QLT – Key Facts
Table 2: QLT – Other Locations and Subsidiaries
Table 3: QLT – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: QLT – Key Events Impacting Share Price Performance
Table 5: QLT – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 6: QLT – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: QLT – Balance Sheet, 2002-2006 ($ Mn)
Table 8: QLT – Cash Flow, 2002-2006 ($ Mn)
Table 9: QLT – Revenue Breakdown by Division, 2002-2006 ($ Mn)
Table 10: QLT – Geographic Breakdown, 2002-2006 ($ Mn)
Table 11: QLT – Marketed Products
Table 12: QLT – In-house Pipeline Products
Table 13: QLT – Historical Product Sales, 2002-2006 ($ Mn)
Table 14: QLT – Key Competitors
Table 15: QLT – Key Clients
Table 16: QLT – Key Shareholders
Table 17: QLT – SWOT Analysis Summary
Table 18: QLT – Value Chain Analysis
Table 19: QLT – Key Employees
Table 20: QLT – Financial and Operational Overview